Global Sustained Release Excipients Market

Sustained Release Excipients Market Size, Share, Growth Analysis, By Product(Gelatin, Polymers, Minerals, Sugars), By Route of Administration(Oral, Intramuscular, Subcutaneous, Transdermal), By Technology(Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35I2231 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 96 | Figures: 76

Sustained Release Excipients Market News

In September 2022, Nutriventia, a company specializing in connecting global suppliers and buyers of food, health, and natural ingredients, introduced a sustained-release Prolanza ashwagandha (Withania somnifera). Prolanza represents a new-age Ashwagandha root-only extract designed to provide extended support for stress management.
In February 2022, Biohaven Pharmaceutical Holding Company Ltd, a clinical-stage biopharmaceutical company, and Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, expressed optimism for rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. They have recommended the 75 mg dose of rimegepant, available as an orally dissolving tablet, for marketing authorization.

Sustained Release Excipients Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Sustained Release Excipients Market size was valued at USD 1.26 billion in 2022 and is poised to grow from USD 1.37 billion in 2023 to USD 2.60 billion by 2031, growing at a CAGR of 8.4% in the forecast period (2024-2031).

The competitive landscape in the market is defined by the several companies engaged in fierce competition to gain a competitive advantage by focusing on R&D to develop new excipient formulations and delivery systems. Market players are employing strategic partnerships and acquisitions to expand their reach. 'Allergan PLC (Ireland)', 'AstraZeneca (UK)', 'GlaxoSmithKline PLC (UK)', 'Mayne Pharma Group Limited (Australia)', 'Mylan NV (US)', 'Novartis AG (Switzerland)', 'Pfizer Inc. (US)', 'Salix Pharmaceuticals (US)', 'Sun Pharmaceutical Industries Ltd (India)', 'Roche Holdings AG (Switzerland)', 'Sanofi (France)', 'Johnson & Johnson (US)', 'Eli Lilly and Company (US)', 'Merck & Co., Inc. (US)', 'Teva Pharmaceutical Industries Ltd (Israel)', 'AbbVie Inc. (US)', 'Bristol-Myers Squibb (US)', 'Gilead Sciences, Inc. (US)', 'Bayer AG (Germany)', 'Takeda Pharmaceutical Company Limited (Japan)'

The constantly aging population is driving this market as the global demographic landscape shifts to an older age population, propelling demand for healthcare products and pharmaceuticals. Sustained release excipients provide benefits like extended drug release to improve compliance and manage chronic conditions effectively, cementing its importance producing medications that cater to the specific needs of elderly patients. As healthcare providers target the healthcare challenges associated with an aging population, this demographic shift will drive steady demand for sustained release excipients in the pharmaceutical sector.

Increased Focus on Personalized Medicine : The growing emphasis on personalized medicine is trending in the pharmaceutical industry, including the sustained release excipients market. Advances in biomarker identification and genomics are targeting the development of medications designed according to individual patient profiles. Sustained excipients enable precise dosing and prompt timing of optimized release in therapeutic outcomes while minimizing side effects, highlighting its significance in formulation of these personalized drug delivery systems. This trend is in line with the shift towards patient-centric healthcare, driving innovation in excipient formulations and technologies.

North America dominates the market due to its thriving pharmaceutical industry, enriched by rigorous R&D, making it a global centre for drug formulation. The adoption of sustained release excipients is being driven further by a strong emphasis on patient-centric healthcare and rigid regulatory standards placed to guarantee drug efficiency and safety. The region’s position in the market is strengthened by its substantial healthcare expenditure and large presence of renowned pharmaceutical companies.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Sustained Release Excipients Market News

Sustained Release Excipients Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Sustained Release Excipients Market?

Who are the key vendors in the Sustained Release Excipients Market?

What is the key driver of Sustained Release Excipients Market?

What is the key market trend for Sustained Release Excipients Market?

Which region accounted for the largest share in Sustained Release Excipients Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300